Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bender, A.
Right arrow Articles by Klopstock, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bender, A.
Right arrow Articles by Klopstock, T.
Related Collections
Right arrow Parkinson's disease/Parkinsonism
Right arrow All Clinical trials
Right arrow Clinical trials Randomized controlled (CONSORT agreement)
NEUROLOGY 2006;67:1262-1264
© 2006 American Academy of Neurology
Brief Communications

Creatine supplementation in Parkinson disease: A placebo-controlled randomized pilot trial

A. Bender, MD, W. Koch, MD, M. Elstner, MD, Y. Schombacher, MD, J. Bender, MD, M. Moeschl, F. Gekeler, MD, B. Müller-Myhsok, MD, T. Gasser, MD, K. Tatsch, MD and T. Klopstock, MD

From the Departments of Neurology (A.B., M.E., Y.S., F.G., T.K.), Nuclear Medicine (W.K., K.T.), and Pharmacology (M.M.), Klinikum Grosshadern, University of Munich, Germany; Max-Planck Institute for Psychiatry (B.M.-M.), Munich, Germany; and Hertie-Institute for Clinical Brain Research, University of Tübingen, Germany (T.G.)

Address correspondence and reprint requests to Dr. Thomas Klopstock, Department of Neurology, Klinikum Grosshadern, University of Munich, Marchioninistr. 15, 81377 Munich, Germany; e-mail: thomas.klopstock{at}med.uni-muenchen.de

Mitochondrial dysfunction plays a major role in the pathogenesis of Parkinson disease (PD). Creatine (Cr) is an ergogenic compound that exerts neuroprotective effects in animal models of PD. We conducted a 2-year placebo-controlled randomized clinical trial on the effect of Cr in 60 patients with PD. Cr improved patient mood and led to a smaller dose increase of dopaminergic therapy but had no effect on overall Unified Parkinson's Disease Rating Scale scores or dopamine transporter SPECT.

T.G. and T.K. received a grant from the Wilhelm-Sander-Stiftung, Munich, Germany. Creatine monohydrate was kindly provided by SKW Trostberg, Germany.

Disclosure: The authors report no conflicts of interest.

Received December 21, 2005. Accepted in final form June 20, 2006.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by AAN Enterprises, Inc.